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Abstract
The identification of Mycobacterium tuberculosis by Ro-
bert Koch in 1882 as the causative agent of tuberculosis,
the release of the drug rifampicin in 1970 and the
sequencing of the M. tuberculosis genome in 1998 are
three major events that have revolutionized tuberculosis
research. In spite of these breakthroughs, the continued
status of tuberculosis as the largest killer amongst infec-
tious diseases is an issue of major concern. Although
directly observed short course chemotherapy exists to
treat the disease, the emergence of drug-resistant strains
has severely threatened the efficacy of the treatment.
The recent sequencing of the M. tuberculosis genome
holds promise for the development of new vaccines and
the design of new drugs. This is all the more possible
when the information from the genome sequence is
combined with proteomics and structural and functional
genomics. Such an integrated approach has led to the
birth of a new field of research christened ‘postgeno-
mics’ that holds substantial promise for the identification
of novel drug targets and the potential to aid the devel-
opment of new chemotherapeutic compounds to treat
tuberculosis. The challenge before the scientific commu-
nity therefore lies in elucidation of the wealth of informa-
tion provided by the genome sequence and its transla-
tion into the design of novel therapies for the disease. All
the major developments in the field of tuberculosis
research after the sequencing of the M. tuberculosis
genome will be discussed in this review.
Copyright © 2004 S. Karger AG, Basel
Introduction
The sequencing of genomes of various pathogenic mi-
crobes has ushered in a most exciting era of medicine.
Recent studies have generated hopes that decoding the
genome of microbial pathogens will assist in the design of
successful intervention strategies that would provide the
host an edge over the pathogen. The genome sequence of
Mycobacterium tuberculosis has provided new dimen-
sions to tuberculosis researchers around the world. Find-
ing a new drug against tuberculosis (TB) will now be large-
ly dependent on our ability to amalgamate postgenomic
information with the newly developed fields of transcrip-
tomics and proteomics. The availability of the mycobac-
terial genome sequence has set up a platform for provision
of answers to questions such as the functioning of the
organism as an integrated system and activity in conjunc-
tion with the host. There are state-of-the-art technologies
that have attempted to provide answers to these ques-
tions. Though genome sequencing definitely reveals more
than ‘the tip of an iceberg’, it still needs to be supple-
mented with additional information such as gene func-
tion, regulation and interactions. A combination of all of
this knowledge holds promise for the development of new
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intervention regimes against TB. This review will attempt
to address some of these issues in a holistic fashion.
Genome Analysis in silico: Potentials of
Bioinformatics
The availability of the genome sequence of various
organisms, prokaryotic as well as eukaryotic, and even
different strains of the same species, as in the case of
M. tuberculosis, Helicobacter pylori etc., has provided im-
mense opportunity for bioinformaticists to play around
with the enormous data generated. With the development
of more efficient bioinformatic tools like Position-Spe-
cific Iterated Basic Local Alignment Search Tool (PSI
BLAST), Cluster of Orthologous Groups (COG), many
genes with unassigned functions are now being annotated
quickly and possibly correctly [1]. The COG database
(http://www.ncbi.nlm.nih.gov/COG/), which is based
upon phylogenetic classification of proteins encoded in
complete genomes, has been used to reannotate the ge-
nomes of various organisms including M. tuberculosis.
Data mining has also been used for accurate prediction of
protein function [2]. When the M. tuberculosis genome
was published [3], around 60% of the genes were labeled
as ‘unknowns’ or ‘hypothetical’. Today, thanks to new
bioinformatic and experimental approaches, this figure
has been reduced to about 48%. In a major effort to rean-
notate the genome, 22 new protein-coding genes, most of
which are shorter than the 100-codon cutoff used initially,
have been identified [4]. However, there are still about
376 proteins that do not have any homologues and are
possibly unique to M. tuberculosis.
The bioinformatic approach has also helped in the
functional classification of protein families. Computa-
tional methods for classification of cyclic nucleotide
(cNMP)-binding protein and nucleotide cyclase super-
families have shown that M. tuberculosis encodes several
more putative cNMP-binding proteins than other pro-
karyotes; the functions of many of these are unknown
[5].
Identification of secreted proteins of M. tuberculosis by
in silico analysis for the presence of N-terminal signal
peptide has also resulted in the identification of about 52
proteins, with experimental proof for about 17 of them
[6]. Functional prediction of these secreted proteins
would be important since it could also lead to the identifi-
cation of proteins that could be important antigens. Re-
gions of the genome that elicit a strong T cell response can
also be exploited for development of a positive disease
outcome. Associated studies include use of advanced and
accurate programs that can predict T cell epitopes in the
context of mycobacterial genome. Development of such
programs along with in vitro methods for screening and
confirming epitopes would increase the pace of develop-
ment of new generation T cell epitope-based vaccines [7].
Bioinformatics has also aided in our understanding of
the possible mechanisms of transcription termination in
M. tuberculosis. Use of specific programs for deciphering
hairpin formation at the 3) end of mRNAs has suggested
that the bacterium does not depend much on hairpin for-
mation for transcription termination [8], hence rho-
dependent transcription termination assumes obvious
significance. Nevertheless, the probable hairpin forming
regions have been evaluated using specific algorithms and
experimental verification of the role of these sequences as
transcription terminators suggests that there is a more or
less relaxed requirement for the U trail in the mycobacte-
rial genome [9]. While the in silico approach does help in
prediction of gene function and in the shortlisting of genes
for functional analysis, all in silico predictions require an
in vivo verification and validation.
Comparative Genomics
With the advancement of sequencing technology, the
number of organisms being sequenced is increasing at a
rapid pace. Amongst the M. tuberculosis complex, M. tu-
berculosis was the first organism to be sequenced followed
by Mycobacterium leprae and Mycobacterium bovis. Se-
quencing of M. bovis BCG, Mycobacterium marinum and
the nonpathogenic bacterium Mycobacterium smegmatis
are in various stages of completion and annotation. The
availability of the genome sequence of related organisms
has dramatically enhanced the study of comparative ge-
nomics [10]. Comparison at the genetic level provides
clues to the possible loss or gain of virulence of one species
as compared to another.
The genome of the leprosy bacillus and the massive
deletions, pseudogenes etc. associated with it makes us
ponder the reasons behind its reductive evolution [11].
Following suggestions that the leprosy bacillus is slowly
heading towards its own death, its genome is being
exploited to understand the complex implications of the
loss of several important genes. It has been suggested that
the loss of sigma factors could also lead to the accumula-
tion of pseudogenes [12].
Chromosomal polymorphism between M. tuberculosis,
M. bovis, and M. bovis BCG Pasteur have also been stud-
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ied using the BAC library of all three [13]. The study
detected a novel 12.7-kb segment present in M. tuberculo-
sis but absent from M. bovis and M. bovis BCG Pasteur.
Analysis of this segment showed that this region contains
genes whose probable products show low similarity to
proteins involved in polysaccharide biosynthesis.
Studies on comparative genomics of various mycobac-
terial species have revealed several deletions that exist in
both virulent and avirulent species. Amongst these dele-
tions, the most widely discussed is the RD1 region that
has been deleted from M. bovis BCG and Mycobacterium
microti [14]. Restoration of RD1 region in BCG by gene
knock-in experiments has shown a clear transformation of
the morphology to virulent type. Upon analysis of this
deleted region, it was found that a few RD1 encoded pro-
teins are localized in the cell wall while others code for
immunodominant T cell antigens: ESAT-6 and CFP-10.
Immunogenicity of the RD1 region has also been estab-
lished using a synthetic peptide approach [15]. While
immunocompetent mice could clear wild-type BCG,
BCG RD1 knock-in showed increased persistence and
partial reversal of attenuation. Five other RD loci were
also tested for their effect on the virulence of BCG. How-
ever, none of them showed a response similar to RD1
knock-ins. A recent report has shown that recombinant
BCG exporting ESAT-6 confers enhanced protection
against TB in mice [16]. In a reverse approach, knocking
out the RD1 region from M. tuberculosis led to reduced
ability of the resultant bacterium to infect human and
mouse macrophage cell lines [17]. These studies point
towards the possibility of development of novel recombi-
nant BCG vaccines.
Comparative genomic analysis of M. tuberculosis and
M. bovis BCG has revealed that there are two major rear-
rangements in the genome of M. bovis BCG Pasteur [18].
These rearrangements correspond to deletion and dupli-
cation of certain regions. Though the significance of these
regions in terms of attenuation of virulence or decreased
immunogenicity of BCG is not known, it nonetheless
reinforces the need to explore their function.
Epidemiological studies for identification of strain-
specific signatures also form an important part of compar-
ative genomics as they guide the understanding of evolu-
tion, and to an extent the pathogenesis, of the organism
[19–21]. Our laboratory has also taken an initiative to
assign specific signatures to strains from various geo-
graphic regions of the world utilizing different techniques
like fluorescent amplified fragment length polymorphism,
MIRU VNTR, spoligotyping, IS1081/6110 typing, etc.
[22, 23]. The availability of the genome sequence has
additionally helped us fine map the unique signatures
associated with virulent strains. One of our studies also
suggests that M. tuberculosis strains from HIV-seroposi-
tive and -seronegative patients are very distinct [24].
Availability of a database on strain-specific signatures
would also help in identification of strains responsible for
outbreaks [25].
Whole Genome Microarray: A Clue to Gene
Expression under Different Conditions
Gene regulation in M. tuberculosis is tightly controlled
by environmental signals and in this context microarray
has become a very important tool for identification of
genes expressed under a variety of growth conditions as
well as for elucidation of the function of regulatory pro-
teins by mutation analysis. Drug-induced alterations in
gene expression have been studied by DNA microarray
technology [26]. Isoniazid-induced genes have been stud-
ied using microarrays. It was found that isoniazid expo-
sure leads to the expression of proteins physiologically rel-
evant to the drug’s mode of action, including an operonic
cluster of five genes encoding type II fatty acid synthase
enzymes and fbpC, which encodes trehalose dimycolyl
transferase. Other genes like efpA, fadE23, fadE24, and
ahpC, which are likely to mediate processes that are
linked to the toxic consequences of the drug, were also
expressed. Identification of these genes may define new
drug targets.
Mycobacterium faces a microaerophilic environment
within the host. Therefore, the hypoxic response genes
become very important for the pathogen. Whole genome
microarray studies identified 1100 genes whose expres-
sion is rapidly altered by defined hypoxic conditions [27].
Many of the genes involved in aerobic metabolism were
found to be repressed. A putative two-component re-
sponse regulator pair Rv3133c/Rv3132c was also found
to be induced in hypoxic conditions. Later studies showed
that Rv3133c is a very important regulator of hypoxic
response [28].
Microarray along with proteomics has been used to
investigate the response of M. tuberculosis to nutrient
starvation [29]. This has provided evidence for slowdown
of the transcription apparatus, energy metabolism, lipid
biosynthesis and cell division in addition to induction of
the stringent response and of several other genes that may
play a role in maintaining long-term survival within the
host. This work has therefore generated a model with
which one can search for agents active against persistent
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M. tuberculosis and has revealed a number of potential
targets expressed under these conditions.
The transcriptional response to low pH that mimics
the environment to which the mycobacteria are exposed
following phagocytosis has been studied by microarray
technology [30]. Eighty-one genes were differentially ex-
pressed 11.5-fold, including many involved in fatty acid
metabolism. The most highly induced genes showed ho-
mologies with those of nonribosomal peptide synthetases/
polyketide synthetases.
Microarray-based information is available on regulato-
ry proteins and several transcription factors of M. tuber-
culosis. The M. tuberculosis genome has 13 annotated sig-
ma factors of which the ECF sigma factor, SigE, has been
shown to contribute to pathogen survival following sever-
al distinct stresses [31]. An alternative sigma factor, SigH,
has also been shown to play a role in mycobacterial stress
response [32]. Survival of an M. smegmatis sigH sigE
double mutant was found to be markedly decreased fol-
lowing 53°C heat shock and exposure to cumene hydro-
peroxide. The expression of the second gene in the sigH
operon is required for complementation of the sigH stress
phenotypes [33]. Role of these two sigma factors, SigH
and SigE, in global gene expression profiles of M. tubercu-
losis has been studied using microarray technology. The
SigH regulon and its role in global regulation of heat shock
response and the thiol-specific oxidizing agent diamide
have been defined using both quantitative RT-PCR and
microarray technology [34]. In this study, 48 genes were
identified whose expression increased after exposure of
M. tuberculosis to diamide. Of these, 39 were not induced
in the sigH mutant, suggesting their direct or indirect reg-
ulation by SigH. Many of these genes include thioredoxin,
thioredoxin reductase and enzymes involved in cysteine
and molybdopterine biosynthesis, which are related to
thiol metabolism. SigH was also shown to be the regulator
of other sigma factors such as SigB, SigE, and SigH itself.
A related study has also shown that the M. tuberculosis
sigH gene is dispensable for bacterial growth and survival
within the host, but is required for the production of
immunopathology and lethality [35].
The role of sigma factors in stress response suggests
that these genes could be involved in pathogenicity. Mi-
croarray studies were carried out with sigE mutant strains
and the SigE regulon was defined after confirmation with
RT-PCR analysis [31]. It was shown that a functional sigE
is required for full expression of sigB and for its induction
after SDS exposure but not after heat shock. Genes no
longer induced in the absence of sigE were also identified.
These genes encode proteins belonging to different classes
including transcription regulators, enzymes involved in
fatty acid degradation and classical heat shock proteins.
Apart from identifying the genes under the regulatory
control of SigE, it was also shown that the sigE mutant is
defective in its ability to grow inside both human and
murine inactivated macrophages and is more sensitive,
than the wild-type strain, to the killing activity of acti-
vated murine macrophages. Thus sigma factors appear to
be attractive drug targets.
Another well-characterized global transcription regula-
tor of M. tuberculosis is the iron-dependent repressor
(IdeR) protein. Postgenomics, in conjunction with mi-
croarray technology, has defined the IdeR regulon [36].
These genes encode a variety of proteins, including puta-
tive transporters, proteins involved in siderophore syn-
thesis and iron storage, members of the PE/PPE family, a
membrane protein involved in virulence, transcription
regulators, and enzymes involved in lipid metabolism. A
PPE member, Rv2430c, that is overexpressed in an IdeR
mutant has recently been characterized in our laboratory
as an immunodominant antigen [37]. IdeR itself is an
attractive drug target as IdeR deletion is lethal in M. tu-
berculosis. A high-resolution structure of IdeR has been
solved [38].
The Phenomenon of Mycobacterial Latency
A major bottleneck in the development of a TB drug or
vaccine has been the ability of Mycobacterium to enter a
phase of dormancy inside the host cells. Postgenomic
studies have shown that the glyoxylate shunt enzyme iso-
citrate lyase is very important for mycobacterial persis-
tence in macrophages and mice [39]. Lipids are the chief
carbon source during the dormant phase of infection and
perhaps that is the reason behind the existence of a large
number of proteins involved with lipid metabolism. The
structure of isocitrate lyase has already been solved [40],
but it has not been feasible to design an inhibitor for this
target as the amount of inhibitor required to block this
actively produced enzyme would be so high that it might
even prove toxic to the host.
Mycobacterial latency has often been linked to hypoxic
conditions within the host. However, response of M. tu-
berculosis to hypoxic conditions has remained poorly
understood. Though microarray analysis has given con-
siderable clues, a recent report represents another break-
through in the understanding of the factors that control
hypoxic response in M. tuberculosis. The transcription
factor that largely regulates hypoxic response has been
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identified [27, 28]. Verification of the role of this putative
transcription factor (Rv3133c/DosR) was carried out by
targeted disruption of the gene followed by analysis of the
transcriptome of the mutant, as well as the wild-type bac-
terium. Induction of the hypoxia-responsive genes was
not observed in the case of mutated dosR.
Conserved DosR binding site was also observed in the
upstream sequences of all the genes under its regulatory
control. The host response in the latent phase has also
been studied in some detail. It has been shown that a
CD8+ subset of T cells is active and produces IFN-Á only
in the latent phase of infection [41].
Our understanding of the physiology of the bacterium
in the latent phase has also been increased by a proteo-
mics approach (identification of the highly up-regulated
genes under hypoxic conditions) using techniques such as
two-dimensional electrophoresis, and protein signature
peptide analysis by liquid chromatography-mass spec-
trometry [42]. Targeting latent bacteria is a challenge.
Using models depicting latency, the genome sequence has
helped in the identification of some genes that allow the
bacteria to control this phase. Targeting these genes would
help in combating the latent phase of infection.
Genomics versus Proteomics: Answers Given
by Proteomics
While the end of the 20th century saw the birth of
genomics, the beginning of the 21st century is witnessing
the birth and a rapid development of proteomics. Pro-
teomics actually complements genomics in demonstrating
which genes are really expressed and translated into a
functional protein. Transcriptomics and proteomics are
two extremely important tools for the identification of
novel drug targets and vaccine candidates. These twin
technologies are dramatically influencing the study of
mycobacterial pathogenesis and virulence.
The power of proteomics suggests that subtle differ-
ences in bacterial culture conditions may have important
implications for gene expression and protein production
in mycobacteria. Study of nutrient starvation in M. smeg-
matis using a proteomics approach led to the identifica-
tion of a nonspecific DNA binding protein, Dps, that has
a role in DNA repair by nonspecific binding [43]. The
M. tuberculosis homologue of Dps could be performing a
similar role. Proteomics study of M. tuberculosis using
two-dimensional electrophoresis and matrix-assisted laser
desorption ionization and nano-electrospray mass spec-
trometry has also been used to identify 6 new proteins of
M. tuberculosis not predicted by genomics methods [44].
A proteomics approach has even been used to identify the
T cell antigens of M. tuberculosis [45]. With increased
emphasis on structural proteomics, it is becoming impor-
tant to quickly shortlist protein targets for structural stud-
ies that will appropriately take into consideration protein
sequences, functions and genomic distribution [46]. Solv-
ing the three-dimensional structure of important proteins
could lead to the design of novel inhibitors and hence the
development of novel drugs.
Bioinformatics has also aided the field of proteomics in
the context of development of methods for clustering pro-
tein sequences and building families of potentially ortho-
logous sequences. In silico analysis of protein similarity
and genetic neighborhood has also been used to under-
stand functional relationships between proteins [47]. This
study observed linkage between genes coding for mem-
brane proteins and those involved in fatty acid metabo-
lism. ESAT6-like transport proteins were also found to
occur with the mce operon. The analysis could also indi-
cate that very few transport proteins are present in the
bacterium, which could be a reflection of its intracellular
lifestyle.
Ensuring a Better Diagnosis for TB
The most popular diagnostic test for TB, the tuberculin
skin test, has limitations on account of background ob-
tained in BCG-vaccinated individuals. Development of
new PCR-based methods for TB diagnosis is gaining
increased popularity on account of their higher specificity
and sensitivity [48]. Comparative genome sequence anal-
ysis has given some clue to the regions that are unique to
M. tuberculosis and which are deleted in the case of BCG.
These regions, which also constitute prominent T cell
antigens like ESAT6, are being exploited to develop a spe-
cific antigen-based diagnostic assay for TB [49].
Novel Drugs and Vaccine Development:
Is It a Near Possibility?
The genomics approach has led to the identification of
genes/proteins important to the pathogen and is progress-
ing fast towards development of a viable vaccine for TB.
However, the challenge lies in selecting the most probable
candidate immunogens or virulence genes from amongst
approximately 4,000 genes of Mycobacterium. The avail-
ability of the genome sequence of pathogens in combina-
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tion with a better understanding of protective pathogen-
specific immune responses has laid the foundations for the
development of new-generation recombinant vaccines. In
the case of TB, recombinant BCG vaccines have gained
much publicity owing to their observed protective efficacy
in model infections. BCG vaccine (rBCG30) expressing
and secreting the 30-kD major secretory protein of M.
tuberculosis, has been shown to be more potent in increas-
ing survival after challenge than parental BCG in the guin-
ea pig model of pulmonary TB [50, 51]. Recombinant
BCG expressing ESAT6 has also been shown to provide
mild protection against TB infection [52]. In a very prom-
ising recent report, recombinant BCG bearing the entire
RD1 deletion region along with the flanking region, which
is predicted to contain the secretory signal, has shown an
enhanced protection in mice [16]. This suggests that the
loss of the ability of BCG to elicit a protective immune
response is due to the loss of important ‘chunks’ of the
genome and that restoration of the same indicates that
there is hope for a better vaccine than BCG.
DNA vaccine for TB is in a likely possibility consid-
ering the report of hsp65-based DNA vaccine providing
protection in mice against intravenous infection with TB
[53]. However, in another study where the major antigens
ESAT6 and Hsp60 were injected into mice as DNA vac-
cines, protection was observed only in the case of intrave-
nous bacterial infection and not in the case of the more
general aerosol mode of infection [54].
While development of a new vaccine for TB is the
prime target of TB research, control of TB by chemothera-
py is also the focus of many laboratories. The increasing
information on the biology of M. tuberculosis and the
availability of the genome sequence have provided a list
of novel drug targets to kill the pathogen. Identification of
new drug targets is important as most of the existing tar-
gets have been altered or mutated by the bacterium [55,
56]. Genomics has given us a brief idea about the com-
plete sets of genes, enzymes and proteins possessed by the
bacterium; subsequent research has already uncovered
several leads for new drug targets.
Genomics has the potential to identify new drug tar-
gets as well as to understand why some drugs are without
effect whereas others are fully active. The M. tuberculosis
genome has been shown to possess a large number of puta-
tive drug efflux pumps, which might be playing an impor-
tant role in imparting resistance to the bacterium. Work
performed in our laboratory has shown that one of the
putative drug efflux pumps is overexpressed in a drug-
resistant clinical isolate of M. tuberculosis [57]. These
pumps could themselves serve as drug targets. Other
important potential drug targets in microbial genomes
could be outer-membrane proteins, host interaction fac-
tors, permeases, enzymes of intermediary metabolism,
systems for DNA replication, transcription, and repair,
translation apparatus, etc. The probable role and essen-
tiality of all these genes should be studied in detail to
develop comprehensive ‘multi-pronged’ combinations of
antibiotics that would fight bacterial pathogens effectively
[58]. Virulence genes, uncharacterized essential genes,
species-specific genes, unique enzymes and drug trans-
porters are also a current focus of research for identifica-
tion of new drug targets [59].
It is paradoxical that while there has been no dearth of
identification of drug targets, no new drug has been intro-
duced into the market even in the postgenomic era. How-
ever, the postgenomic era has suggested a few promising
drugs for the disease such as the nitroimidazopyrans, a
class of drugs that inhibit the biosynthesis of protein and
cell wall lipids [60]. These drugs could target replicating as
well as nondividing bacteria and have potent bactericidal
activity against multidrug-resistant bacteria.
It is presumed that the application of functional ge-
nomic tools, such as microarray and proteomics, in com-
bination with modern approaches, such as structure-
based drug design and combinatorial chemistry, will lead
to the development of new drugs that are not only active
against drug-resistant TB but can also shorten the course
of TB therapy.
Conclusion
Sequencing alone will not bring about a paradigm shift
in medical research but a thorough understanding of its
implications will definitely ensure that such a change will
take place. The initial outcome of any genome sequencing
project is just an unpunctuated string of 4 letters (A, T, G,
C). Genomics involves compiling this information and
postgenomics involves mining useful information from
the genome. The genome approach has been applied to
TB and the targets set by commercial companies and
research institutions support optimism that a permanent
cure for the disease is not a distant vision.
Acknowledgments
The research in Dr. Hasnain’s laboratory cited in this review was
supported by grants from the Department of Biotechnology and
Council of Scientific and Industrial Research (CSIR), Government
of India. P.C. thanks the CSIR for a Senior Research Fellowship.
Mandate of Tuberculosis Research in a
Postgenomic Era
Med Princ Pract 2004;13:177–184 183
References
1 Muller A, MacCallum RM, Sternberg MJ:
Benchmarking PSI-BLAST in genome annota-
tion. J Mol Biol 1999;293:1257–1271.
2 King RD, Karwath A, Clare A, Dehaspe L:
Accurate prediction of protein functional class
from sequence in the Mycobacterium tubercu-
losis and Escherichia coli genomes using data
mining. Yeast 2000;17:283–293.
3 Cole ST, Brosch R, Parkhill J, Garnier T,
Churcher C, Harris D, Gordon SV, Eiglmeier
K, Gas S, Barry CE 3rd, Tekaia F, Badcock K,
Basham D, Brown D, Chillingworth T, Connor
R, Davies R, Devlin K, Feltwell T, Gentles S,
Hamlin N, Holroyd S, Hornsby T, Jagels K,
Krogh A, Mclean J, Moule S, Murphy L, Oliver
K, Osborne J, Quail MA, Rajani MA, Rogers J,
Rutter S, Seeger K, Skelton J, Squares R,
Squares S, Sulston JE, Taylor K, Whitehead S,
Barrell BG: Deciphering the biology of Myco-
bacterium tuberculosis from the complete ge-
nome sequence. Nature 1998;11:537–544. Er-
ratum in: Nature 1998;396:190.
4 Camus JC, Pryor MJ, Medigue C, Cole ST: Re-
annotation of the genome sequence of Myco-
bacterium tuberculosis H37Rv. Microbiology
2002;148:2967–2973.
5 McCue LA, McDonough KA, Lawrence CE:
Functional classification of cNMP-binding
proteins and nucleotide cyclases with implica-
tions for novel regulatory pathways in Myco-
bacterium tuberculosis. Genome Res 2000;10:
204–219. 
6 Gomez M, Johnson S, Gennaro ML: Identifica-
tion of secreted proteins of Mycobacterium tu-
berculosis by a bioinformatic approach. Infect
Immun 2000;68:2323–2327.
7 Sbai H, Mehta A, DeGroot AS: Use of T cell
epitopes for vaccine development. Curr Drug
Targets Infect Disord 2001;1:303–313.
8 Washio T, Sasayama J, Tomita M: Analysis of
complete genomes suggests that many proka-
ryotes do not rely on hairpin formation in tran-
scription termination. Nucleic Acids Res 1998;
26:5456–5463.
9 Unniraman S, Prakash R, Nagaraja V: Alter-
nate paradigm for intrinsic transcription termi-
nation in eubacteria. J Biol Chem 2001;276:
41850–41855.
10 Brosch R, Gordon SV, Pym A, Eiglmeier K,
Garnier T, Cole ST: Comparative genomics of
the mycobacteria. Int J Med Microbiol 2000;
290:143–152.
11 Cole ST, Eiglmeier K, Parkhill J, James KD,
Thomson NR, Wheeler PR, Honore N, Gar-
nier T, Churcher C, Harris D, Mungall K,
Basham D, Brown D, Chillingworth T, Connor
R, Davies RM, Devlin K, Duthoy S, Feltwell T,
Fraser A, Hamlin N, Holroyd S, Hornsby T,
Jagels K, Lacroix C, Maclean J, Moule S, Mur-
phy L, Oliver K, Quail MA, Rajandream MA,
Rutherford KM, Rutter S, Seeger K, Simon S,
Simmonds M, Skelton J, Squares R, Squares S,
Stevens K, Taylor K, Whitehead S, Woodward
JR, Barrell BG: Massive gene decay in the
leprosy bacillus. Nature 2001;409:1007–1011.
12 Madan Babu M: Did the loss of sigma factors
initiate pseudogene accumulation in M. leprae?
Trends Microbiol 2003;11:59–61.
13 Brosch R, Gordon SV, Billault A, Garnier T,
Eiglmeier K, Soravito C, Barrell BG, Cole ST:
Use of a Mycobacterium tuberculosis H37Rv
bacterial artificial chromosome library for ge-
nome mapping, sequencing, and comparative
genomics. Infect Immun 1998;66:2221–2229.
14 Pym AS, Brodin P, Brosch R, Huerre M, Cole
ST: Loss of RD1 contributed to the attenuation
of the live tuberculosis vaccines Mycobacte-
rium bovis BCG and Mycobacterium microti.
Mol Microbiol 2002;46:709–717.
15 Mustafa AS, Cockle PJ, Shaban F, Hewinson
RG, Vordermeier HM: Immunogenicity of
Mycobacterium tuberculosis RD1 region gene
products in infected cattle. Clin Exp Immunol
2002;130:37–42.
16 Pym AS, Brodin P, Majlessi L, Brosch R, De-
mangel C, Williams A, Griffiths KE, Marchal
G, Leclerc C, Cole ST: Recombinant BCG
exporting ESAT-6 confers enhanced protection
against tuberculosis. Nat Med 2003;9:533–
539.
17 Lewis KN, Liao R, Guinn KM, Hickey MJ,
Smith S, Behr MA, Sherman DR: Deletion of
RD1 from Mycobacterium tuberculosis mimics
bacille Calmette-Guérin attenuation. J Infect
Dis 2003;187:117–123.
18 Brosch R, Gordon SV, Buchrieser C, Pym AS,
Garnier T, Cole ST: Comparative genomics
uncovers large tandem chromosomal duplica-
tions in Mycobacterium bovis BCG Pasteur.
Yeast 2000;17:111–123.
19 Tazi L, Kreiswirth B, Carriere C, Tibayrenc M:
Molecular epidemiology of Mycobacterium tu-
berculosis and its relevance to the surveillance
and control of TB: An e-debate. Infect Genet
Evol 2002;2:153–158.
20 Hasnain SE: Molecular epidemiology of infec-
tious diseases: A case for increased surveil-
lance. Bull World Health Organ 2003;81:474.
21 Alland D, Whittam TS, Murray MB, Cave
MD, Hazbon MH, Dix K, Kokoris M, Duester-
hoeft A, Eisen JA, Fraser CM, Fleischmann
RD: Modeling bacterial evolution with com-
parative-genome-based marker systems: Appli-
cation to Mycobacterium tuberculosis evolu-
tion and pathogenesis. J Bacteriol 2003;185:
3392–3399.
22 Siddiqi N, Shamim M, Amin A, Chauhan DS,
Das R, Srivastava K, Singh D, Sharma VD,
Katoch VM, Sharma SK, Hanief M, Hasnain
SE: Typing of drug resistant isolates of Myco-
bacterium tuberculosis from India using the
IS6110 element reveals substantive polymor-
phism. Infect Genet Evol 2001;1:109–116.
23 Ahmed N, Alam M, Abdul Majeed A, Asad
Rahman S, Cataldi A, Cousins D, Hasnain SE:
Genome sequence based, comparative analysis
of the fluorescent amplified fragment length
polymorphisms (FAFLP) of tubercle bacilli
from seals provides molecular evidence for a
new species within the Mycobacterium tubercu-
losis complex. Infect Genet Evol 2003;2:193–
199.
24 Ahmed N, Caviedes L, Alam M, Rao KR, San-
gal V, Sheen P, Gilman RH, Hasnain SE: Dis-
tinctiveness of Mycobacterium tuberculosis ge-
notypes from human immunodeficiency virus
type 1-seropositive and -seronegative patients
in Lima, Peru. J Clin Microbiol 2003;41:1712–
1716.
25 Raman LA, Siddiqi N, Shamim M, Deb M,
Mehta G, Hasnain SE: Molecular characteriza-
tion of Mycobacterium abscessus strains iso-
lated from a hospital outbreak. Emerg Infect
Dis 2000;6:561–562.
26 Wilson M, DeRisi J, Kristensen HH, Imboden
P, Rane S, Brown PO, Schoolnik GK: Explor-
ing drug-induced alterations in gene expression
in Mycobacterium tuberculosis by microarray
hybridization. Proc Natl Acad Sci USA 1999;
96:12833–12838.
27 Sherman DR, Voskuil M, Schnappinger D,
Liao R, Harrell MI, Schoolnik GK: Regulation
of the Mycobacterium tuberculosis hypoxic re-
sponse gene encoding alpha-crystallin. Proc
Natl Acad Sci USA 2001;98:7534–7539.
28 Park HD, Guinn KM, Harrell MI, Liao R, Vos-
kuil MI, Tompa M, Schoolnik GK, Sherman
DR: Rv3133c/dosR is a transcription factor
that mediates the hypoxic response of Myco-
bacterium tuberculosis. Mol Microbiol 2003;
48:833–843.
29 Betts JC, Lukey PT, Robb LC, McAdam RA,
Duncan K: Evaluation of a nutrient starvation
model of Mycobacterium tuberculosis persis-
tence by gene and protein expression profiling.
Mol Microbiol 2002;43:717–731.
30 Fisher MA, Plikaytis BB, Shinnick TM: Mi-
croarray analysis of the Mycobacterium tuber-
culosis transcriptional response to the acidic
conditions found in phagosomes. J Bacteriol
2002;184:4025–4032.
31 Manganelli R, Voskuil MI, Schoolnik GK,
Smith I: The Mycobacterium tuberculosis ECF
sigma factor sigmaE: Role in global gene ex-
pression and survival in macrophages. Mol Mi-
crobiol 2001;41:423–437.
32 Raman S, Song T, Puyang X, Bardarov S,
Jacobs WR Jr, Husson RN: The alternative sig-
ma factor SigH regulates major components of
oxidative and heat stress responses in Myco-
bacterium tuberculosis. J Bacteriol 2001;183:
6119–6125.
33 Fernandes ND, Wu QL, Kong D, Puyang X,
Garg S, Husson RN: A mycobacterial extracy-
toplasmic sigma factor involved in survival fol-
lowing heat shock and oxidative stress. J Bac-
teriol 1999;181:4266–4274.
184 Med Princ Pract 2004;13:177–184 Chakhaiyar/Hasnain
34 Manganelli R, Voskuil MI, Schoolnik GK,
Dubnau E, Gomez M, Smith I: Role of the
extracytoplasmic-function sigma factor sig-
ma(H) in Mycobacterium tuberculosis global
gene expression. Mol Microbiol 2002;45:365–
374.
35 Kaushal D, Schroeder BG, Tyagi S, Yoshimat-
su T, Scott C, Ko C, Carpenter L, Mehrotra J,
Manabe YC, Fleischmann RD, Bishai WR: Re-
duced immunopathology and mortality despite
tissue persistence in a Mycobacterium tubercu-
losis mutant lacking alternative sigma factor,
SigH. Proc Natl Acad Sci USA 2002;99:8330–
8335.
36 Rodriguez GM, Voskuil MI, Gold B, Schoolnik
GK, Smith I: ideR, an essential gene in Myco-
bacterium tuberculosis: Role of IdeR in iron-
dependent gene expression, iron metabolism,
and oxidative stress response. Infect Immun
2002;70:3371–3381.
37 Choudhary RK, Mukhopadhyay S, Chakhaiyar
P, Sharma N, Murthy KJR, Katoch VM, Has-
nain SE: PPE antigen Rv2430c of Mycobacte-
rium tuberculosis induces a strong B-cell re-
sponse. Infect Immun 2003;71:6338–6343.
38 Feese MD, Ingason BP, Goranson-Siekierke J,
Holmes RK, Hol WG: Crystal structure of the
iron-dependent regulator from Mycobacterium
tuberculosis at 2.0-A resolution reveals the Src
homology domain 3-like fold and metal bind-
ing function of the third domain. J Biol Chem
2001;276:5959–5966.
39 McKinney JD, Honer zu Bentrup K, Munoz-
Elias EJ, Miczak A, Chen B, Chan WT, Swen-
son D, Sacchettini JC, Jacobs WR Jr, Russell
DG: Persistence of Mycobacterium tuberculosis
in macrophages and mice requires the glyoxy-
late shunt enzyme isocitrate lyase. Nature
2000;406:735–738.
40 Sharma V, Sharma S, Hoener zu Bentrup K,
McKinney JD, Russell DG, Jacobs WR Jr, Sac-
chettini JC: Structure of isocitrate lyase, a per-
sistence factor of Mycobacterium tuberculosis.
Nat Struct Biol 2000;7:663–668.
41 Van Pinxteren LA, Cassidy JP, Smedegaard
BH, Agger EM, Andersen P: Control of latent
Mycobacterium tuberculosis infection is depen-
dent on CD8 T cells. Eur J Immunol 2000;30:
3689–3698.
42 Rosenkrands I, Slayden RA, Crawford J, Aa-
gaard C, Barry CE 3rd, Andersen P: Hypoxic
response of Mycobacterium tuberculosis stud-
ied by metabolic labeling and proteome analy-
sis of cellular and extracellular proteins. J Bac-
teriol 2002;184:3485–3491.
43 Gupta S, Pandit SB, Srinivasan N, Chatterji D:
Proteomics analysis of carbon-starved Myco-
bacterium smegmatis: Induction of Dps-like
protein. Protein Eng 2002;15:503–512.
44 Jungblut PR, Muller EC, Mattow J, Kaufmann
SH: Proteomics reveals open reading frames in
Mycobacterium tuberculosis H37Rv not pre-
dicted by genomics. Infect Immun 2001;69:
5905–5907.
45 Covert BA, Spencer JS, Orme IM, Belisle JT:
The application of proteomics in defining the T
cell antigens of Mycobacterium tuberculosis.
Proteomics 2001;1:574–586.
46 Abascal F, Valencia A: Clustering of proximal
sequence space for the identification of protein
families. Bioinformatics 2002;18:908–921.
47 Tekaia F, Gordon SV, Garnier T, Brosch R,
Barrell BG, Cole ST: Analysis of the proteome
of Mycobacterium tuberculosis in-silico. Tuber
Lung Dis 1999;79:329–342.
48 Su WJ: Recent advances in the molecular diag-
nosis of tuberculosis. J Microbiol Immunol In-
fect 2002;35:209–214.
49 Gennaro ML: Immunologic diagnosis of tuber-
culosis. Clin Infect Dis 2000;30(suppl 3):S243–
246.
50 Horwitz MA, Harth G, Dillon BJ, Maslesa-
Galic’ S: Recombinant bacillus Calmette-
Guérin (BCG) vaccines expressing the Myco-
bacterium tuberculosis 30-kDa major secretory
protein induce greater protective immunity
against tuberculosis than conventional BCG
vaccines in a highly susceptible animal model.
Proc Natl Acad Sci USA 2000;97:13853–
13858.
51 Horwitz MA, Harth G: A new vaccine against
tuberculosis affords greater survival after chal-
lenge than the current vaccine in the guinea pig
model of pulmonary tuberculosis. Infect Im-
mun 2003;71:1672–1679.
52 Bao L, Chen W, Zhang H, Wang X: Virulence,
immunogenicity, and protective efficacy of two
recombinant Mycobacterium bovis bacillus
Calmette-Guérin strains expressing the antigen
ESAT-6 from Mycobacterium tuberculosis. In-
fect Immun 2003;71:1656–1661.
53 Lowrie DB, Tascon RE, Bonato VLD, Lima
Valeria MF, Faccioli LH, Stavropoulos E, Col-
ston MJ, Hewinson RG, Moelling K, Silva CL:
Therapy of tuberculosis in mice by DNA vacci-
nation. Nature 1999;400:269–271.
54 Taylor JL, Turner OC, Basaraba RJ, Belisle JT,
Huygen K, Orme IM: Pulmonary necrosis re-
sulting from DNA vaccination against tubercu-
losis. Infect Immun 2003;71:2192–2198.
55 Siddiqi N, Shamim M, Jain NK, Rattan A,
Amin A, Katoch VM, Sharma SK, Hasnain SE:
Molecular genetic analysis of multi-drug resis-
tance in Indian isolates of Mycobacterium tu-
berculosis. Mem Inst Oswaldo Cruz 1998;93:
589–594.
56 Siddiqi N, Shamim M, Hussain S, Choudhary
RK, Ahmed N, Prachee C, Banerjee S, Savithri
GR, Alam M, Pathak N, Amin A, Hanief M,
Katoch VM, Sharma SK, Hasnain SE: Molecu-
lar characterization of multidrug-resistant iso-
lates of Mycobacterium tuberculosis from pa-
tients in North India. Antimicrob Agents Che-
mother 2002;46:443–450.
57 Siddiqi N, Das R, Pathak N, Banerjee S,
Ahmed N, Katoch VM, Hasnain SE: Mycobac-
terium tuberculosis isolate with a distinct ge-
nomic identity overexpresses a TAP like efflux
pump. Infection 2004; in press.
58 Galperin MY, Koonin E: Searching for drug
targets in microbial genomes. Curr Opin Bio-
technol 1999;10:571–578.
59 Smith I: Mycobacterium tuberculosis pathogen-
esis and molecular determinants of virulence.
Clin Microbiol Rev 2003;16:463–496.
60 Kendall SC, Warrener P, Vandevanter DR,
Sherman DR, Arain TM, Langhorne MH, An-
derson SW, Towell JA, Yuan Y, McMurray
DN, Kreiswirth BN, Barry CE, Baker WR: A
small-molecule nitroimidazopyran drug candi-
date for the treatment of tuberculosis. Nature
2000;405:962–966.
